Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rucaparib PFS Benefit in Recurrent OC Across Age Groups

Publish date:: March 28, 2019

Key clinical point: The improved progression-free survival seen with maintenance rucaparib vs. placebo in ARIEL3 occurred across age subgroups.

Major finding: PFS with rucaparib vs. placebo did not differ significantly across age subgroups (HR, 0.33, 0.43, 0.47 for those under age 65, aged 65-74, and 75+, respectively).

Study details: A post hoc analysis of data for 564 patients in the ARIEL3 study.

Disclosures: ARIEL3 was funded by Clovis Oncology. Dr. Ledermann reported financial relationships (consulting, grant receipt, honorarial reimbursement, and/or speakers bureau fees) with AstraZeneca, Clovis Oncology, Pfizer, Seattle Genetics, Roche, and MSD/Merck.

Citation:

Ledermann J et al. SGO 2019, Abstract 4.

This Week's Must Reads

Some MCL patients can safely stop venetoclax-ibrutinib, study suggests,

BCL11A-directed gene therapy advances in sickle cell disease,

KTE-X19 produces highest response rate in MCL subgroup,

Residual cancer burden linked to long-term survival,

House passes drug pricing bill, likely ending its journey,

Must Reads in Gynecologic Cancer

Sequential CRT, immunotherapy nets high PFS in node-positive cervical cancer,

In recurrent ovarian cancer, secondary surgery does not extend survival,

Surgical Staging Improves Cervical Cancer Outcomes,

Sentinel node biopsy safe for women with vulval cancer,

HER2-Positive Solid Tumors: Molecule Exhibits Antitumor Activity,